\
&
Contact us
\
&
Contact us
This was 1 year ago
Locationonline
ProgrammesHave you already been involved in a EU-funded project (H2020) focused on innovative renewable energy technologies? Then this is a webinar for you.
This event is taking place as part of the EU-funded DIAMONDS4IF and REALIZE projects. These latter support the development of Innovation Fund-ready projects by ensuring project viability, preparing applicants for Innovation Fund applications, and fostering collaboration across stakeholders, investors, and the value chain to accelerate the European decarbonisation efforts.
During the webinar they will explain to interested applicants and Horizon project coordinators the application process for the Innovation Fund and the Hydrogen Auction Programme. They will provide essential information, support and help to seize future funding opportunities in order to maximise the number of high-quality applications for the upcoming Innovation Fund calls scheduled for 3 December 2024.
More information can be found here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
